Anand V Kulkarni

anandvkulkarni.bsky.social

13 May 2025 09:46

With rising burden of metabolic diseases we are struggling with management of ascites in CKD. Here we try to answer them & provide an overview of approach to ascites in ESRD. @ebtapper.bsky.social @akashroyy.bsky.social journals.lww.com/hepcomm/full...

Edgar V. Lerma 🇵🇭

edgarvlermamd.medsky.network

27 April 2025 13:12

Rhabdomyolysis induced AKI: Key 🔑 pathobiological processes and management interventions ca. 2023 #Nephpearls 👉🏼 journals.lww.com/cjasn/pages/...

Edgar V. Lerma 🇵🇭

edgarvlermamd.medsky.network

27 April 2025 13:09

Finerenone trials #PSHPLAS 🇵🇭 #Nephpearls #NephSky 👉🏼 FIDELIO pubmed.ncbi.nlm.nih.gov/33264825/ 👉🏼 FIGARO pubmed.ncbi.nlm.nih.gov/34449181/ 👉🏼 FIDELITY pubmed.ncbi.nlm.nih.gov/35023547/ 👉🏼 FINE-HEART pubmed.ncbi.nlm.nih.gov/39218030/

Joel Topf

kidneyboy.bsky.social

23 April 2025 03:38

I love that from 2009 to 2017 the @goKDIGO CKD-MBD guideline 4.2.2 changed from this to that without irony (or a change in evidence level)

Edgar V. Lerma 🇵🇭

edgarvlermamd.medsky.network

21 April 2025 02:48

AKI in Cirrhosis: Management (based on etiology) #Nephpearls #NKFClinicals 🇺🇸 #NephSky